Abstract: A first edible layer is placed atop a tray and inside a first annular member, leaving an annular gap around the edible layer. A spreadable material is spread atop and laterally on the first edible layer. A second annular member is stacked upon the first annular member with a second edible layer centered in the second member but with an annular gap between the two. Spreadable material atop and laterally to the second edible layer. The annular members each have an overall transverse dimension greater than its height. These members are part of a reusable kit with the first member has an outwardly projecting pair of handles A tool for shaping spreadable material is shown as a plate with an opposite pair of finishing edges, one being straight, the other undulating. The lower edge of the tool is located between the finishing edges, and has an opposite pair of guide notches. Each of the notches can be pressed against the edge of the tray to regulate the tool's working depth.

Abstract: A first edible layer is placed atop a tray and inside a first annular member, leaving an annular gap around the edible layer. A spreadable material is spread atop and laterally on the first edible layer. A second annular member is stacked upon the first annular member with a second edible layer centered in the second member but with an annular gap between the two. Spreadable material atop and laterally to the second edible layer. The annular members each have an overall transverse dimension greater than its height. These members are part of a reusable kit with the first member has an outwardly projecting pair of handles A tool for shaping spreadable material is shown as a plate with an opposite pair of finishing edges, one being straight, the other undulating. The lower edge of the tool is located between the finishing edges, and has an opposite pair of guide notches. Each of the notches can be pressed against the edge of the tray to regulate the tool's working depth.

Abstract: A pharmaceutical composition comprises a drug-carrier system having a small-molecule drug of low water solubility, e.g. N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N?-(2-fluoro-5-methylphenyl)urea (ABT-869), and (+)-1-(5-tert-butyl-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102), in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The drug-carrier system, when mixed with an aqueous phase, typically forms a non-gelling, substantially non-transparent liquid dispersion. The composition is suitable for administration by a suitable route, e.g. orally, to a subject in need thereof.

Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof.

Abstract: The present invention is directed to a formulation comprising a lipid-regulating agent dissolved in at least one monoglyceride as the primary solvent medium for said agent. One or more emulsifiers may be added to the formulation.

Abstract: Two new crystalline polymorphs of the compound of formula (I) 1

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).

Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).